It is reported that "Jicui Yaokang" has recently completed more than 400 million yuan of B round financing. This round of financing is led by Hillhouse Venture Capital, with the participation of Yunfeng Fund, Morgan Stanley Investment Management Fund, Sequoia Capital China Fund, Taifu Capital and other funds, which is a new round of financing after the 160 million yuan A round of financing of "Jicui Yaokang" in 2019. This round of funds will be mainly used to promote the layout of global production capacity and the construction of new technology research and development platforms.
Founded in 2017, "Jicui Yaokang" is a high-tech biotechnology enterprise specializing in the development of mouse disease models and humanized models, and is also a co-construction unit of the National Genetic Engineering Mouse Resource Library. The management team of "Jicui Yaokang" was formerly known as the operation management team of Nanjing University-Nanjing Institute of Biomedicine, and the founder, Professor Gao Xiang, was the director of the National Genetic Engineering Mouse Resource Bank.
Institute of Artificial Model and Drug Screening Innovation Technology
Animal models are an indispensable experimental tool in early scientific research and drug preclinical development, and are used to replace the human body to verify the efficacy of preclinical drugs. Mice can simulate many human disease symptoms through gene editing and are considered the most important model animals. With the rapid growth of antibody drug research and development and biological therapy in the Chinese market, the Chinese mouse model market has also ushered in a huge development opportunity.
At present, through independent development, "Jicui Yaokang" has created hundreds of mouse strains with humanized immune system and humanized liver, and constructed a resource bank of protein-coding gene knockout mice including tens of thousands of strains. The company has established R&D and production bases in Nanjing, Changzhou, Guangdong, Foshan, Guangdong and Chengdu, Sichuan, and the total number of breeding cages will exceed 150,000 by the end of 2020. The WHOlly-owned subsidiary of "Jicui Yaokang" has been registered and has begun to expand into the international market.
In addition, the customers of "Jicui Yaokang" cover most pharmaceutical companies, CRO companies and scientific research institutions in China, including Many well-known pharmaceutical companies such as Novartis, GSK, Hengrui, BeiGene, etc., well-known CROOs such as WuXi AppTec, Sino-US Crown Science and Technology, Zhaoyan, and many famous scientific research institutions and universities such as the Chinese Academy of Sciences, the Chinese Academy of Medicine and The Double First-class University.
Further reading: 36Kr debuts | Providing an animal model platform for innovative drugs around the world, "Jicui Yaokang" received 160 million yuan of Series A financing from CDH and Sinopharm
Editor: Cai Shuning
![Constructing a model animal domestic dog model, Sino Valley Biology won the national key scientific topic[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)